NKA Bio develops novel therapeutics aimed at stabilizing critically ill trauma patients suffering from shock. Their lead candidate, NKA01, is an anti-shock toxin antibody designed for immediate injection by EMS personnel in the field. This intervention seeks to temporarily halt physiological decline, thereby extending the window for transport and definitive surgical care.
Funding
$400K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traumatic injuries often lead to shock, the leading cause of death for individuals aged 1 to 44, resulting from the body's response to the injury rather than the injury itself. Current emergency medical protocols lack effective interventions to delay the onset of shock, limiting the time available for patients to reach trauma centers and receive life-saving surgical care.
Solution
NKA Bio is developing NKA01, a temperature-stable, anti-shock toxin antibody designed to be administered by emergency medical services at the point of injury. NKA01 aims to stabilize trauma patients by mitigating the effects of shock, effectively pausing the progression towards death and extending the critical time window for transport to trauma centers. This low-volume injection is intended to integrate seamlessly into existing EMS treatment protocols, buying additional hours for life-saving surgical intervention and improving patient outcomes. The antibody engineering platform screens millions of antibodies to predict the ones that bind best.
Target Audience
The primary target audience includes emergency medical technicians (EMTs), paramedics, and other first responders who require a field-deployable solution to stabilize trauma patients and extend the window for effective treatment.
Features
- Temperature-stable formulation for reliable field use by EMS personnel
- Low-volume injection suitable for rapid administration during standard treatment protocols
- Anti-shock toxin antibody designed to neutralize the body's response to trauma
- Designed to delay the onset of shock, providing additional time for transport to trauma centers
- Antibody engineering platform to screen and predict antibodies that bind best